Lewy body Dementia - Pipeline Review, H2 2016

  • ID: 3939715
  • Report
  • 48 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Axovant Sciences Ltd.
  • BioArctic AB
  • Eisai Co., Ltd.
  • Immungenetics AG
  • MORE
Lewy body Dementia - Pipeline Review, H2 2016

Summary

‘Lewy body Dementia - Pipeline Review, H2 2016’, provides an overview of the Lewy body Dementia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lewy body Dementia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lewy body Dementia and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note - : Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Lewy body Dementia
- The report reviews pipeline therapeutics for Lewy body Dementia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Lewy body Dementia therapeutics and enlists all their major and minor projects
- The report assesses Lewy body Dementia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Lewy body Dementia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Lewy body Dementia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lewy body Dementia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Axovant Sciences Ltd.
  • BioArctic AB
  • Eisai Co., Ltd.
  • Immungenetics AG
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Lewy body Dementia Overview

Therapeutics Development

Pipeline Products for Lewy body Dementia - Overview

Lewy body Dementia - Therapeutics under Development by Companies

Lewy body Dementia - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Lewy body Dementia - Products under Development by Companies

Lewy body Dementia - Companies Involved in Therapeutics Development

Axovant Sciences Ltd.

BioArctic AB

Eisai Co., Ltd.

Immungenetics AG

Sumitomo Dainippon Pharma Co., Ltd.

Takeda Pharmaceutical Company Limited

Lewy body Dementia - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(donepezil hydrochloride + glycopyrrolate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(glycopyrrolate + rivastigmine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAN-0805 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-2027 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

intepirdine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nelotanserin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate ABC Transporter for Neurodegeneration Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize M1 Muscarinic Acetylcholine Receptor for Lewy Body Dementia and Parkinson's Disease Dementia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-071 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-915 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zonisamide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lewy body Dementia - Dormant Projects

Lewy body Dementia - Product Development Milestones

Featured News & Press Releases

Apr 21, 2016: FAU site for first US clinical trial for Lewy Body dementia

Feb 09, 2016: Axovant Sciences Announces Launch Of First-In-Class Clinical Programs Of RVT-101 For Lewy Body Dementia

Feb 09, 2016: Axovant Sciences Announces Launch Of First-In-Class Clinical Programs Of Nelotanserin For Lewy Body Dementia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Lewy body Dementia, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Lewy body Dementia - Pipeline by Axovant Sciences Ltd., H2 2016

Lewy body Dementia - Pipeline by BioArctic AB, H2 2016

Lewy body Dementia - Pipeline by Eisai Co., Ltd., H2 2016

Lewy body Dementia - Pipeline by Immungenetics AG, H2 2016

Lewy body Dementia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016

Lewy body Dementia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Lewy body Dementia - Dormant Projects, H2 2016 42List of Figures

Number of Products under Development for Lewy body Dementia, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Axovant Sciences Ltd.
  • BioArctic AB
  • Eisai Co., Ltd.
  • Immungenetics AG
  • MORE
Lewy body Dementia Lewy Body Dementia (also called Dementia with Lewy bodies) is a form of dementia that shares characteristics with both Alzheimer's and Parkinson's diseases. Lewy bodies are abnormal microscopic protein deposits in the brain that disrupt the brain's normal functioning causing it to slowly deteriorate. Symptoms include visual hallucinations, movement disorders, cognitive problems and depression. Risk factors include age and family history. Treatment includes cholinesterase inhibitors, antipsychotic and Parkinson's disease medications.

Lewy body Dementia pipeline therapeutics constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 5, 2 and 1 respectively.

Our latest report Lewy body Dementia – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Lewy body Dementia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Lewy body Dementia and features dormant and discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Axovant Sciences Ltd.
BioArctic AB
Eisai Co., Ltd.
Immungenetics AG
Sumitomo Dainippon Pharma Co., Ltd.
Takeda Pharmaceutical Company Limited
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll